Published in J Biol Chem on January 06, 2012
HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol (2013) 1.07
Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One (2012) 0.93
The M-T hook structure is critical for design of HIV-1 fusion inhibitors. J Biol Chem (2012) 0.87
Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol (2013) 0.87
Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652. J Biol Chem (2012) 0.87
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses (2012) 0.86
Computer-Aided Approaches for Targeting HIVgp41. Biology (Basel) (2012) 0.82
Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK. Retrovirology (2014) 0.80
Structural basis of potent and broad HIV-1 fusion inhibitor CP32M. J Biol Chem (2012) 0.79
Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket. J Virol (2015) 0.79
Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41. Curr HIV Res (2016) 0.77
DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes. Antimicrob Agents Chemother (2013) 0.77
DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity. Nucleic Acid Ther (2015) 0.75
Creating an artificial tail-anchor as a novel strategy to enhance the potency of peptide-based HIV fusion inhibitors. J Virol (2016) 0.75
Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction Assay. Avicenna J Med Biotechnol (2013) 0.75
A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activities against HIV-1, HIV-2 and Simian Immunodeficiency Virus. J Virol (2016) 0.75
PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52
MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2009) 53.36
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
HIV entry and its inhibition. Cell (1998) 9.42
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat Struct Biol (1996) 8.57
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A (1994) 8.48
A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol (1995) 7.30
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
HIV-1 inhibition by a peptide. Nature (1993) 5.01
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol (1998) 4.48
The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol (2003) 4.21
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A (2009) 3.92
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 3.60
The changing face of HIV in China. Nature (2008) 3.39
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov (2004) 2.46
Understanding the genetic diversity of HIV-1. AIDS (2000) 2.39
Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog (2010) 2.33
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A (2007) 2.02
Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS (2004) 2.00
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother (2002) 1.82
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2008) 1.74
The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr (2010) 1.67
AIDS virus envelope spike structure. Curr Opin Struct Biol (2007) 1.54
Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem (2007) 1.34
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol (2010) 1.33
Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J Biol Chem (2011) 1.33
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses (1998) 1.27
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci U S A (2008) 1.25
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J Virol (2008) 1.20
Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J Virol (2008) 1.16
SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother (2008) 1.15
HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res (2003) 1.14
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol (2007) 1.14
Inhibiting HIV-1 entry with fusion inhibitors. Curr Med Chem (2003) 1.13
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem (2009) 1.11
Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China. Retrovirology (2009) 1.10
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis (2005) 1.07
In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2010) 1.03
Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochim Biophys Acta (2011) 0.99
Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J Acquir Immune Defic Syndr (2008) 0.98
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology (2005) 0.95
Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr Pharm Des (2010) 0.93
Predicted co-receptor tropism and sequence characteristics of China HIV-1 V3 loops: implications for the future usage of CCR5 antagonists and AIDS vaccine development. Int J Infect Dis (2009) 0.89
Discontinuation of the clinical development of fusion inhibitor T-1249. AIDS Rev (2004) 0.86
Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors. AIDS (2005) 0.86
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
Inhibitor hijacking of Akt activation. Nat Chem Biol (2009) 4.91
A critical assessment of Mus musculus gene function prediction using integrated genomic evidence. Genome Biol (2008) 4.78
Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell (2009) 4.71
Cytosolic viral sensor RIG-I is a 5'-triphosphate-dependent translocase on double-stranded RNA. Science (2009) 4.00
The unfolded protein response signals through high-order assembly of Ire1. Nature (2008) 3.87
Bypassing a kinase activity with an ATP-competitive drug. Science (2003) 3.71
Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell (2006) 3.32
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci U S A (2009) 3.05
A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 2.93
Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev (2003) 2.79
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother (2004) 2.76
Chemical genetic analysis of Apg1 reveals a non-kinase role in the induction of autophagy. Mol Biol Cell (2003) 2.72
Selective amygdalohippocampectomy versus anterior temporal lobectomy in the management of mesial temporal lobe epilepsy: a meta-analysis of comparative studies. J Neurosurg (2013) 2.71
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol (2005) 2.51
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol (2007) 2.43
Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A (2007) 2.37
Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci Signal (2010) 2.36
JNK2 is a positive regulator of the cJun transcription factor. Mol Cell (2006) 2.32
Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature (2010) 2.25
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol (2009) 2.23
Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell (2007) 2.22
An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol (2008) 2.21
TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol (2009) 2.20
Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc Natl Acad Sci U S A (2008) 2.19
Modulation of protein properties in living cells using nanobodies. Nat Struct Mol Biol (2009) 2.15
Re-emerging superconductivity at 48 kelvin in iron chalcogenides. Nature (2012) 2.13
An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 2.11
Biochemical analysis of the DNA unwinding and strand annealing activities catalyzed by human RECQ1. J Biol Chem (2005) 2.11
The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med (2015) 2.07
Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling. J Cell Biol (2010) 2.07
The Saccharomyces cerevisiae Mob2p-Cbk1p kinase complex promotes polarized growth and acts with the mitotic exit network to facilitate daughter cell-specific localization of Ace2p transcription factor. J Cell Biol (2002) 2.04
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology (2005) 2.03
Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses. PLoS Pathog (2013) 1.99
Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc Natl Acad Sci U S A (2003) 1.93
A global representation of the protein fold space. Proc Natl Acad Sci U S A (2003) 1.88
Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem (2005) 1.87
IFITM proteins restrict viral membrane hemifusion. PLoS Pathog (2013) 1.86
Phosphorylation of the transcription elongation factor Spt5 by yeast Bur1 kinase stimulates recruitment of the PAF complex. Mol Cell Biol (2009) 1.82
Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol (2005) 1.79
Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol (2009) 1.78
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75
Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol (2012) 1.74
The regulatory domain of the RIG-I family ATPase LGP2 senses double-stranded RNA. Nucleic Acids Res (2009) 1.72
Chemical genetics reveals a role for Mps1 kinase in kinetochore attachment during mitosis. Curr Biol (2005) 1.70
Cdc28-Clb5 (CDK-S) and Cdc7-Dbf4 (DDK) collaborate to initiate meiotic recombination in yeast. Genes Dev (2008) 1.68
Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc Natl Acad Sci U S A (2007) 1.67
The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1. Proc Natl Acad Sci U S A (2005) 1.67
TFIIH and P-TEFb coordinate transcription with capping enzyme recruitment at specific genes in fission yeast. Mol Cell (2009) 1.66
Mek1 kinase activity functions downstream of RED1 in the regulation of meiotic double strand break repair in budding yeast. Mol Biol Cell (2003) 1.66
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell (2004) 1.64
Global mapping of the protein structure space and application in structure-based inference of protein function. Proc Natl Acad Sci U S A (2005) 1.59
Chemical genetic inhibition of Mps1 in stable human cell lines reveals novel aspects of Mps1 function in mitosis. PLoS One (2010) 1.50
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
[Responses of spatial distribution pattern of Artemisia ordosica population to the precipitation gradient on Ordos Plateau]. Ying Yong Sheng Tai Xue Bao (2009) 1.44
Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol (2011) 1.44
Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2 subunits. J Biol Chem (2007) 1.43
Human Ago2 is required for efficient microRNA 122 regulation of hepatitis C virus RNA accumulation and translation. J Virol (2010) 1.42
A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. Chem Biol (2007) 1.42
A genetically selective inhibitor demonstrates a function for the kinase Zap70 in regulatory T cells independent of its catalytic activity. Nat Immunol (2010) 1.42
Access denied: Snf1 activation loop phosphorylation is controlled by availability of the phosphorylated threonine 210 to the PP1 phosphatase. J Biol Chem (2007) 1.42
Engineering the cell-material interface for controlling stem cell adhesion, migration, and differentiation. Biomaterials (2011) 1.41
Design and use of analog-sensitive protein kinases. Curr Protoc Mol Biol (2004) 1.37
Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol (2011) 1.37
RECQ1 helicase interacts with human mismatch repair factors that regulate genetic recombination. J Biol Chem (2005) 1.36
Optimal fine φ-slicing for single-photon-counting pixel detectors. Acta Crystallogr D Biol Crystallogr (2011) 1.36
Different quaternary structures of human RECQ1 are associated with its dual enzymatic activity. PLoS Biol (2007) 1.36
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine (2006) 1.36
Room temperature giant and linear magnetoresistance in topological insulator Bi2Te3 nanosheets. Phys Rev Lett (2012) 1.34
Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther (2007) 1.33
Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Mol Cell (2008) 1.32
Structure and substrate recruitment of the human spindle checkpoint kinase Bub1. Mol Cell (2008) 1.32
Protein kinase Cdelta regulates ethanol intoxication and enhancement of GABA-stimulated tonic current. J Neurosci (2008) 1.32
Construction of conditional analog-sensitive kinase alleles in the fission yeast Schizosaccharomyces pombe. Nat Protoc (2007) 1.32
The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine (2009) 1.32
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res (2003) 1.32
Intraglottal pressure distributions for a symmetric and oblique glottis with a uniform duct. J Acoust Soc Am (2002) 1.31
Rapid self-healing hydrogels. Proc Natl Acad Sci U S A (2012) 1.29
Orm protein phosphoregulation mediates transient sphingolipid biosynthesis response to heat stress via the Pkh-Ypk and Cdc55-PP2A pathways. Mol Biol Cell (2012) 1.28
Dynamic phosphoregulation of the cortical actin cytoskeleton and endocytic machinery revealed by real-time chemical genetic analysis. J Cell Biol (2003) 1.27
Internal fixation of distal tibiofibular syndesmotic injuries: a systematic review with meta-analysis. Int Orthop (2013) 1.23
FastContact: rapid estimate of contact and binding free energies. Bioinformatics (2005) 1.22
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology (2009) 1.22
Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol Cell (2011) 1.21
Crystal structure of human enterovirus 71 3C protease. J Mol Biol (2011) 1.20
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii. J Med Chem (2013) 1.19
Tissue-specific PKA inhibition using a chemical genetic approach and its application to studies on sperm capacitation. Proc Natl Acad Sci U S A (2008) 1.18
Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc Natl Acad Sci U S A (2006) 1.18
Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling. J Biol Chem (2008) 1.15
Chemical inactivation of cdc7 kinase in budding yeast results in a reversible arrest that allows efficient cell synchronization prior to meiotic recombination. Genetics (2006) 1.15